The c-MET/HGF pathway has gained considerable interest through its apparent deregulation by overexpression or gain-of-function mutations in c-MET in various cancers, including lung cancer (Maulik et al, 2002c; Ma et al, 2003b; Christensen et al, 2005). This evidence concerns the gene MET and lung cancer.